Long-Term Efficacy of AAV9-U7snRNA-Mediated Exon 51 Skipping in mdx52 Mice
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Systemic treatment of mdx52 mice with an AAV serotype 9 (AAV9)-U7 targeting exon 51 vector induced ∼5% exon 51 skipping in the cortex, hippocampus and cerebellum of these mice, which was too little to restore dystrophin protein and address the behavioural deficits (Aupy et al., 2020).”
From Understanding Duchenne muscular dystrophy-associated brain pathology (2025) · cites this paper as Aupy et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456
Hinderer, C., Katz, N., Buza, E. L., Dyer, C., Goode, T., Bell, P., Richman, L. K., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.015 · Cited by 814
Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Duan, D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.011 · Cited by 489
Pre-existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy
Louis Jeune, V., Joergensen, J. A., Hajjar, R. J., & Weber, T. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.243 · Cited by 358
Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy
Le Guiner, C., Servais, L., Montus, M., Larcher, T., Fraysse, B., Moullec, S., Allais, M., François, V., Dutilleul, M., Malerba, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms16105 · Cited by 246 · cited 1×
“Following many encouraging preclinical studies in mice and dogs, 8,9 several clinical trials have been launched to evaluate this strategy in the clinic.”
BackgroundInfluentialHumoral immune response to AAV
Calcedo, R., & Wilson, J. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00341 · Cited by 243 · cited 1×
“The humoral response is also a challenge for patients with pre-existing AAV neutralizing antibodies 37,38 who are usually excluded from AAV trials.”
BackgroundMingozzi, F., & High, K. A. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041936 · Cited by 206 · cited 1×
“Besides the humoral response, the adaptive immune response is often discussed in AAV gene therapy, and the T cell response to AAV capsid has been reported in many trials.(9,39) As an additional hurdle, recent studies suggest that activation of the innate immune response may be a significant concern for high-dose syste…”
BackgroundComplement Is an Essential Component of the Immune Response to Adeno-Associated Virus Vectors
Zaiss, A. K., Cotter, M. J., White, L. R., Clark, S. A., Wong, N. C. W., Holers, V. M., Bartlett, J. S., & Muruve, D. A. (2008) · Journal of Virology · doi:10.1128/jvi.01990-07 · Cited by 177
Research works printed but not linked: 35
- Koenig, 1989, The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion, Am. J. Hum. Genet., 45, 498
- Monaco, 1988, An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus, Genomics, 2, 90, 10.1016/0888-7543(88)90113-9 · DOI · Paper page
- Pramono, 1996, Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence, Biochem. Biophys. Res. Commun., 226, 445, 10.1006/bbrc.1996.1375 · DOI
- Dunckley, 1998, Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides, Hum. Mol. Genet., 7, 1083, 10.1093/hmg/7.7.1083 · DOI · Paper page
- Mann, 2001, Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse, Proc. Natl. Acad. Sci. USA, 98, 42, 10.1073/pnas.98.1.42 · DOI · Paper page
- Aartsma-Rus, 2006, Therapeutic modulation of DMD splicing by blocking exonic splicing enhancer sites with antisense oligonucleotides, Ann. N Y Acad. Sci., 1082, 74, 10.1196/annals.1348.058 · DOI
- Echevarría, 2018, Exon-skipping advances for Duchenne muscular dystrophy, Hum. Mol. Genet., 27, R163, 10.1093/hmg/ddy171 · DOI
- Crudele, 2019, AAV-based gene therapies for the muscular dystrophies, Hum. Mol. Genet., 28, R102, 10.1093/hmg/ddz128 · DOI · Paper page
- Goyenvalle, 2004, Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping, Science, 306, 1796, 10.1126/science.1104297 · DOI · Paper page
- Schümperli, 2004, The special Sm core structure of the U7 snRNP: far-reaching significance of a small nuclear ribonucleoprotein, Cell. Mol. Life Sci., 61, 2560, 10.1007/s00018-004-4190-0 · DOI
- Goyenvalle, 2012, Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping, Hum. Mol. Genet., 21, 2559, 10.1093/hmg/dds082 · DOI
- Goyenvalle, 2012, Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy, Mol. Ther., 20, 1212, 10.1038/mt.2012.26 · DOI
- Vulin, 2012, Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping, Mol. Ther., 20, 2120, 10.1038/mt.2012.181 · DOI
- Aartsma-Rus, 2009, Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations, Hum. Mutat., 30, 293, 10.1002/humu.20918 · DOI · Paper page
- Araki, 1997, Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy, Biochem. Biophys. Res. Commun., 238, 492, 10.1006/bbrc.1997.7328 · DOI · Paper page
- Bremmer-Bout, 2004, Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides, Mol. Ther., 10, 232, 10.1016/j.ymthe.2004.05.031 · DOI
- ’t Hoen, 2008, Generation and characterization of transgenic mice with the full-length human DMD gene, J. Biol. Chem., 283, 5899, 10.1074/jbc.M709410200 · DOI
- Zincarelli, 2010, Comparative cardiac gene delivery of adeno-associated virus serotypes 1–9 reveals that AAV6 mediates the most efficient transduction in mouse heart, Clin. Transl. Sci., 3, 81, 10.1111/j.1752-8062.2010.00190.x · DOI · Paper page
- Aoki, 2010, In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse, Mol. Ther., 18, 1995, 10.1038/mt.2010.186 · DOI
- Sekiguchi, 2009, A deficit of brain dystrophin impairs specific amygdala GABAergic transmission and enhances defensive behaviour in mice, Brain, 132, 124, 10.1093/brain/awn253 · DOI · Paper page
- Vaillend, 2017, Relationships linking emotional, motor, cognitive and GABAergic dysfunctions in dystrophin-deficient mdx mice, Hum. Mol. Genet., 26, 1041
- Yamamoto, 2010, Reduction of abnormal behavioral response to brief restraint by information from other mice in dystrophin-deficient mdx mice, Neuromuscul. Disord., 20, 505, 10.1016/j.nmd.2010.05.006 · DOI · Paper page
- Helleringer, 2018, Cerebellar synapse properties and cerebellum-dependent motor and non-motor performance in Dp71-null mice, Dis. Model. Mech., 11, 10.1242/dmm.033258 · DOI · Paper page
- Rouillon, 2015, Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies, Hum. Mol. Genet., 24, 4916, 10.1093/hmg/ddv214 · DOI
- Relizani, 2017, Efficacy and safety profile of tricyclo-DNA antisense oligonucleotides in Duchenne muscular dystrophy mouse model, Mol. Ther. Nucleic Acids, 8, 144, 10.1016/j.omtn.2017.06.013 · DOI · Paper page
- Spitali, 2013, DMD transcript imbalance determines dystrophin levels, FASEB J., 27, 4909, 10.1096/fj.13-232025 · DOI · Paper page
- Ruszczak, 2009, Differential stabilities of alternative exon-skipped rod motifs of dystrophin, Biochim. Biophys. Acta, 1794, 921, 10.1016/j.bbapap.2009.02.016 · DOI
- Sahni, 2012, Exon edited dystrophin rods in the hinge 3 region, Biochim. Biophys. Acta, 1824, 1080, 10.1016/j.bbapap.2012.06.011 · doi:10.1016/j.bbapap.2012.06.011
- McCourt, 2015, In vitro stability of therapeutically relevant, internally truncated dystrophins, Skelet. Muscle, 5, 13, 10.1186/s13395-015-0040-z · DOI
- Beggs, 1991, Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies, Am. J. Hum. Genet., 49, 54
- Carsana, 2005, Analysis of dystrophin gene deletions indicates that the hinge III region of the protein correlates with disease severity, Ann. Hum. Genet., 69, 253, 10.1046/J.1469-1809.2005.00160.x · doi:10.1046/j.1469-1809.2005.00160.x
- Goyenvalle, 2015, Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers, Nat. Med., 21, 270, 10.1038/nm.3765 · DOI · Paper page
- Le Hir, 2013, AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy, Mol. Ther., 21, 1551, 10.1038/mt.2013.121 · DOI · Paper page
- Dias Florencio, 2015, Simple downstream process based on detergent treatment improves yield and in vivo transduction efficacy of adeno-associated virus vectors, Mol. Ther. Methods Clin. Dev., 2, 15024, 10.1038/mtm.2015.24 · DOI · Paper page
- Aruga, 2004, Locomotor and oculomotor impairment associated with cerebellar dysgenesis in Zic3-deficient (Bent tail) mutant mice, Eur. J. Neurosci., 20, 2159, 10.1111/j.1460-9568.2004.03666.x · DOI
Cited by
Understanding Duchenne muscular dystrophy-associated brain pathology
Verhaeg, M. A. T., Govaarts, R., & van Putten, M. (2025) · Disease Models & Mechanisms · doi:10.1242/dmm.052302 · Cited by 5
Metadata
- Authors
- Aupy, P., Zarrouki, F., Sandro, Q., Gastaldi, C., Buclez, P.-O., Mamchaoui, K., Garcia, L., Vaillend, C., & Goyenvalle, A.
- Venue
- Molecular Therapy - Methods & Clinical Development
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 17
- Pages
- 1037-1047
- ISSN
- 2329-0501
- Cited by
- 43
- References
- 8
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- Association Française contre les Myopathies
- National Center of Neurology and Psychiatry
- Agence Nationale de la Recherche
- Institut National de la Santé et de la Recherche Médicale
- Fondation pour la Recherche Médicale (PLP20161036676)
- Centre National de la Recherche Scientifique
- Duchenne Parent Project
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-Term Efficacy of AAV9-U7snRNA-Mediated Exon 51 Skipping in mdx52 Mice. https://app.cochat.ai/papers/10.1016/j.omtm.2020.04.025
- The paper
- Aupy, P., Zarrouki, F., Sandro, Q., Gastaldi, C., Buclez, P.-O., Mamchaoui, K., Garcia, L., Vaillend, C., & Goyenvalle, A. (2020). Long-Term Efficacy of AAV9-U7snRNA-Mediated Exon 51 Skipping in mdx52 Mice. Molecular Therapy - Methods & Clinical Development. https://doi.org/10.1016/j.omtm.2020.04.025
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.